The recent publication of the GAP70+ study in The Lancet is an important step in the field of geriatric oncology. This study shows that combining a geriatric assessment with oncologic and geriatric management recommendations has the potential to decrease toxicity. We discuss the implications of the study, performed in the United States, for clinical practice and future research in the Netherlands. The results of the GAP70+ study are promising, and the study has landmark potential. Although there are relevant differences in oncologic care between the Netherlands and the United states, this study provides new opportunities for expanding and improving geriatric oncology care.